- Home
- FRAF vs CHRS Comparison
FRAF vs CHRS Comparison
Compare FRAF & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRAF
- CHRS
- Stock Information
- Founded
- FRAF 1906
- CHRS 2010
- Country
- FRAF United States
- CHRS United States
- Employees
- FRAF N/A
- CHRS N/A
- Industry
- FRAF Major Banks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRAF Finance
- CHRS Health Care
- Exchange
- FRAF Nasdaq
- CHRS Nasdaq
- Market Cap
- FRAF 206.3M
- CHRS 186.0M
- IPO Year
- FRAF N/A
- CHRS 2014
- Fundamental
- Price
- FRAF $48.52
- CHRS $1.13
- Analyst Decision
- FRAF
- CHRS Strong Buy
- Analyst Count
- FRAF 0
- CHRS 4
- Target Price
- FRAF N/A
- CHRS $4.51
- AVG Volume (30 Days)
- FRAF 24.4K
- CHRS 1.3M
- Earning Date
- FRAF 10-28-2025
- CHRS 11-06-2025
- Dividend Yield
- FRAF 2.70%
- CHRS N/A
- EPS Growth
- FRAF 9.43
- CHRS N/A
- EPS
- FRAF 3.50
- CHRS 1.34
- Revenue
- FRAF $77,783,000.00
- CHRS $277,728,000.00
- Revenue This Year
- FRAF N/A
- CHRS N/A
- Revenue Next Year
- FRAF N/A
- CHRS $109.48
- P/E Ratio
- FRAF $13.94
- CHRS $0.84
- Revenue Growth
- FRAF 8.75
- CHRS 152.07
- 52 Week Low
- FRAF $28.01
- CHRS $0.71
- 52 Week High
- FRAF $49.66
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FRAF 61.22
- CHRS 29.26
- Support Level
- FRAF $48.43
- CHRS $1.09
- Resistance Level
- FRAF $49.66
- CHRS $1.39
- Average True Range (ATR)
- FRAF 0.97
- CHRS 0.13
- MACD
- FRAF 0.30
- CHRS -0.05
- Stochastic Oscillator
- FRAF 63.95
- CHRS 5.59
About FRAF Franklin Financial Services Corporation
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.